- Home
- RNAZ vs BGLC Comparison
RNAZ vs BGLC Comparison
Compare RNAZ & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- BGLC
- Stock Information
- Founded
- RNAZ 2016
- BGLC 2017
- Country
- RNAZ United States
- BGLC Malaysia
- Employees
- RNAZ N/A
- BGLC N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- RNAZ Health Care
- BGLC Health Care
- Exchange
- RNAZ Nasdaq
- BGLC Nasdaq
- Market Cap
- RNAZ 7.2M
- BGLC 5.8M
- IPO Year
- RNAZ 2021
- BGLC N/A
- Fundamental
- Price
- RNAZ $0.53
- BGLC $0.25
- Analyst Decision
- RNAZ Strong Buy
- BGLC
- Analyst Count
- RNAZ 1
- BGLC 0
- Target Price
- RNAZ $20.00
- BGLC N/A
- AVG Volume (30 Days)
- RNAZ 16.6M
- BGLC 1.5M
- Earning Date
- RNAZ 05-14-2025
- BGLC 05-14-2025
- Dividend Yield
- RNAZ N/A
- BGLC N/A
- EPS Growth
- RNAZ N/A
- BGLC N/A
- EPS
- RNAZ N/A
- BGLC N/A
- Revenue
- RNAZ N/A
- BGLC $9,259,858.00
- Revenue This Year
- RNAZ $180.81
- BGLC N/A
- Revenue Next Year
- RNAZ N/A
- BGLC N/A
- P/E Ratio
- RNAZ N/A
- BGLC N/A
- Revenue Growth
- RNAZ N/A
- BGLC N/A
- 52 Week Low
- RNAZ $0.43
- BGLC $0.21
- 52 Week High
- RNAZ $66.33
- BGLC $1.00
- Technical
- Relative Strength Index (RSI)
- RNAZ 28.52
- BGLC 35.57
- Support Level
- RNAZ $0.43
- BGLC $0.23
- Resistance Level
- RNAZ $0.61
- BGLC $0.29
- Average True Range (ATR)
- RNAZ 0.17
- BGLC 0.02
- MACD
- RNAZ 0.21
- BGLC -0.01
- Stochastic Oscillator
- RNAZ 8.24
- BGLC 20.22
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.